SCHEMBL6891301

SCHEMBL6891301

CCCCNC(=O)[C@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)N(CCC(C)C)[C@@H](CO)Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
REN P00797 1/20 0.46
CHRNB2 P17787 1/20 0.45
CHRNB4 P30926 1/20 0.45
CHRNA3 P32297 1/20 0.45
CHRNA4 P43681 1/20 0.45
MME P08473 3/20 0.45
ACE P12821 3/20 0.45
CPA1 P15085 2/20 0.45
ACE2 Q9BYF1 2/20 0.45
PLG P00747 2/20 0.43
PRSS1 P07477 2/20 0.43
PRSS2 P07478 2/20 0.43
PRSS3 P35030 2/20 0.43
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
PTPN1 P18031 3/20 0.42
PTPRA P18433 1/20 0.42
BCHE P06276 1/20 0.41
PSMB5 P28074 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6897813 0.89 L3MBTL1 (0.46) L3MBTL1RENCHRNB2CHRNB4CHRNA3
SCHEMBL6899412 0.85 MME (0.49) L3MBTL1RENCHRNB2CHRNB4CHRNA3
SCHEMBL6895064 0.84 L3MBTL1 (0.43) L3MBTL1RENCHRNB2CHRNB4CHRNA3
SCHEMBL6895067 0.84 L3MBTL1 (0.43) L3MBTL1RENCHRNB2CHRNB4CHRNA3
SCHEMBL6895445 0.82 MMP2 (0.47) L3MBTL1RENMMP9MMP8
SCHEMBL6895453 0.82 MMP2 (0.47) L3MBTL1RENMMP9MMP8
SCHEMBL6890577 0.81 MME (0.47) L3MBTL1RENCHRNB2CHRNB4CHRNA3
SCHEMBL6899389 0.80 L3MBTL1 (0.40) L3MBTL1RENCHRNB2CHRNB4CHRNA3
SCHEMBL6899397 0.80 L3MBTL1 (0.40) L3MBTL1RENCHRNB2CHRNB4CHRNA3
SCHEMBL27562656 0.80 MMP1 (0.49) MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
CN-1299344-A Novel urea derivatives SANTEN PHARCEUMATICAL CO LTD (JP) 2001-06-13 CN disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH L3MBTL1 3448/4885REN 114/4885CHRNB2 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.